Compound Screening and Marketing - Drug Discovery Digest

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Compound Screening

Marketing

Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities

Sygnature Discovery

JANUARY 17, 2023

Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications. SB is based in Glasgow and employs 55 people.

Compound Screening

Compound Screening Marketing Assay Development Drugs

[Panel Webinar] How to tap into pharma’s $100bn digital transformation opportunity

The Pharma Data

JANUARY 6, 2021

The pharma industry is witnessing a steep rise in the use of AI-driven solutions in early-stage drug discovery, deep-learning technologies for compound screening, and lead identification and automation enhancements in the lab. Presenters: Dr. Haydn Boehm, Head of Commercial Marketing – Connected Lab at Merck Group.

Cell Based Assays

Cell Based Assays Compound Screening Organic Chemistry DNA

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities

[Panel Webinar] How to tap into pharma’s $100bn digital transformation opportunity

Webinars

Stay Connected